

Department of Psychiatry and Neurosciences

USF Health · College of Medicine

Office of the Chair - Week of November 22 – 26, 2010

Website: <http://www.hsc.usf.edu/PSYCH/>

Newsletter

Meetings

Thursday 11/25/10

HOLIDAY - HAPPY THANKSGIVING!

Friday 11/26/10

HOLIDAY - HAPPY THANKSGIVING!

In The Know

On Monday, December 13, 2010, the College of Public Health Dean's Lecture Series presents "Traumatic Brain Injury, Prisoners, and Impulsivity" by Dr. Peter Schofield, Clinical Director of Neuropsychiatry Service at the University of Newcastle, Australia. This lecture will be held at 12:00 noon in the Samuel P. Bell, III Auditorium, Room 1023, at the College of Public Health. Dr. Schofield is currently a Conjoint Associate Professor in Psychiatry at the University of Newcastle, Director of the Neuropsychiatry Service of Hunter New England Area Health, and a Senior Staff Specialist in Neurology.

Research Happenings!

Research Facts

Did you know... the Department has a new Research web page – see <http://health.usf.edu/medicine/psychiatry/research/index.htm>

What else didn't you know :

1. >50% of all new patients seen in our outpatient clinic want information on research being done in our department.
2. Participants in clinical trials receive psychiatric evaluations and follow-up visits; study specific testing (psychiatric, cognitive, behavioral, and health outcomes); labs; ECGs; physical exams; study medication; transportation assistance; 24/7 access to research team, a small stipend; and in some studies, medication vouchers for concomitant medications – all at NO COST.
3. The Department has a new Research web page - see <http://health.usf.edu/medicine/psychiatry/research/index.htm>

What else didn't you know:

Current Open Studies – Call [813-974-2832](tel:813-974-2832) or [813-974-1404](tel:813-974-1404) for more information on any study or to refer a patient.

Abilify IM Depot Study

The Aripiprazole IM Depot Study extension has been extended! Participants in this study can now continue to receive **open-label Aripiprazole IM Depot until it is FDA approved up to a maximum of 8 years**. Our site can enroll up to **49 6 additional subjects in this study until October**. Participants are started on oral Abilify – once tolerability is determined, the participant is switched to Aripiprazole IM Depot. Aripiprazole IM Depot is administered monthly. All study related medications, labs, ECGs and study visits are at no charge to participants throughout the duration of the extension study (remember up to 8 years or until drug is FDA approved). Principal Investigator – Carlos Santana, M.D.

Cognitive Deficits in Schizophrenia

We are participating in a nationwide clinical research trial evaluating the safety and efficacy of an investigational medication used in the treatment of **Cognitive Deficits in Schizophrenia**. This is a 12 week 'ad on medication' study for individuals with schizophrenia between the ages of 20-55. To be eligible subjects must have been *diagnosed or treated* for at least 2 years prior to screening and be stable on 1-2 atypical antipsychotic medications. Principal Investigator - Carlos Santana, M.D.

Bipolar I Disorder with Depressive Symptoms

The Department is participating in a nationwide clinical research study evaluating the efficacy and safety of an investigational medication used as **adjunctive therapy** in patients with **major depression associated with Bipolar I Disorder**. This is a 15-week outpatient study. Patients must be 18-65 years of age and currently experiencing depressive symptoms. Patients must be on Lithium, Depakote, Lamictal, Abilify, Zyprexa, Risperdal, CONSTA, or Geodon. Assistance in obtaining Lithium and Depakote is available during the course of the study. Principal Investigator – Carlos Santana, M.D.

Schizophrenia 'Jail Recidivism' Study

We are one of 40 sites in the United States participating site for this landmark study looking at arrest recidivism in adults with Schizophrenia. The study is a **15-month open-label study** comparing the rate of arrest recidivism and other health outcome measures in patients receiving **oral antipsychotic treatment compared to paliperidone palmitate injections**. Participants receive antipsychotic medications and study visits at no charge throughout the study. Subjects must have been incarcerated at least twice in the last 24 months with the last release from jail occurring within 60 days prior to screening to be eligible to participate.

Principal Investigator – Brian Keefe, M.D.